Literature DB >> 26019194

Analysis of Vancomycin Susceptibility Testing Results for Presumptive Categorization of Telavancin.

Rodrigo E Mendes1, David J Farrell2, Robert K Flamm2, Helio S Sader2, Ronald N Jones2.   

Abstract

Scattergrams between vancomycin and telavancin demonstrated susceptibility agreement rates of 99.96, 99.65, and 100.00% for Staphylococcus aureus, Enterococcus faecalis, and streptococci, respectively. A single very major error was obtained against E. faecalis, while vancomycin-intermediate S. aureus (VISA) and vancomycin-resistant and teicoplanin-susceptible (VanB phenotype) E. faecalis were responsible for major and minor errors. These results support the use of vancomycin to infer telavancin susceptibility among indicated pathogens, except VISA, which should be tested for telavancin susceptibility.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26019194      PMCID: PMC4508411          DOI: 10.1128/JCM.00611-15

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  2 in total

1.  Baseline activity of telavancin against Gram-positive clinical isolates responsible for documented infections in U.S. hospitals (2011-2012) as determined by the revised susceptibility testing method.

Authors:  Rodrigo E Mendes; David J Farrell; Helio S Sader; Robert K Flamm; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2014-10-27       Impact factor: 5.191

2.  Update of the telavancin activity in vitro tested against a worldwide collection of Gram-positive clinical isolates (2013), when applying the revised susceptibility testing method.

Authors:  Rodrigo E Mendes; David J Farrell; Helio S Sader; Jennifer M Streit; Ronald N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  2014-12-31       Impact factor: 2.803

  2 in total
  5 in total

1.  Evaluation of telavancin susceptibility in isolates of Staphylococcus aureus with reduced susceptibility to vancomycin.

Authors:  Allison R McMullen; William Lainhart; Meghan A Wallace; Angela Shupe; Carey-Ann D Burnham
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-08-24       Impact factor: 3.267

Review 2.  Intrathecal Antibacterial and Antifungal Therapies.

Authors:  Roland Nau; Claudia Blei; Helmut Eiffert
Journal:  Clin Microbiol Rev       Date:  2020-04-29       Impact factor: 26.132

3.  Efficacy of Telavancin Alone and in Combination with Ampicillin in a Rat Model of Enterococcus faecalis Endocarditis.

Authors:  Truc T Tran; Vincent H Tam; Barbara E Murray; Cesar A Arias; Kavindra V Singh
Journal:  Antimicrob Agents Chemother       Date:  2017-05-24       Impact factor: 5.191

4.  Emergence of Clinical Clostridioides difficile Isolates With Decreased Susceptibility to Vancomycin.

Authors:  Charles Darkoh; Kadiatou Keita; Chioma Odo; Micah Oyaro; Eric L Brown; Cesar A Arias; Blake M Hanson; Herbert L DuPont
Journal:  Clin Infect Dis       Date:  2022-01-07       Impact factor: 9.079

5.  How to measure the impacts of antibiotic resistance and antibiotic development on empiric therapy: new composite indices.

Authors:  Josie S Hughes; Amy Hurford; Rita L Finley; David M Patrick; Jianhong Wu; Andrew M Morris
Journal:  BMJ Open       Date:  2016-12-16       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.